文献速递头颈部肿瘤放疗

鼻咽癌化疗Meta分析(MAC-NPC):26项试验和7080例患者的更新

Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients.
PubMed 文献 · Clin Transl Radiat Oncol · 2021-11-26

该Meta分析纳入26项随机试验共7080例非转移性鼻咽癌患者,评估放疗联合化疗的疗效。化疗联合放疗降低死亡风险(HR 0.79, 95%CI 0.73-0.85),5年和10年绝对生存获益分别为6.1%和8.4%。同期+辅助化疗、诱导化疗(两组均含同期化疗)和同期化疗获益最大,且化疗获益随患者年龄增加而减小。

要点

  • 化疗联合放疗降低死亡风险,HR 0.79(95%CI 0.73-0.85)。
  • 5年和10年绝对生存获益分别为6.1%和8.4%。
  • 同期+辅助化疗HR 0.68,诱导化疗HR 0.73,同期化疗HR 0.81。

核心结论

  • 该更新Meta分析证实同期化疗和同期+辅助化疗的获益,并提示在同期化疗基础上增加诱导或辅助化疗可改善肿瘤控制和生存。
  • 化疗获益随患者年龄增加而减小。

研究设计与样本

  • 纳入已发表或未发表的随机试验,评估非转移性鼻咽癌患者放疗(±第二化疗时相)联合或不联合化疗。
  • 共纳入26项试验、7080例患者,其中18项为新检索到的试验,7项可获得个体患者数据。
  • 按意向性治疗原则采用固定效应模型分析,主要终点为总生存期,治疗方案按化疗时相分为五个亚组。

主要发现

  • 化疗联合放疗降低死亡风险,HR 0.79(95%CI 0.73-0.85)。
  • 5年和10年绝对生存获益分别为6.1%(95%CI +3.9至+8.3)和8.4%(95%CI +5.7至+11.1)。
  • 同期+辅助化疗HR 0.68(95%CI 0.59-0.79),5年绝对生存获益12.3%(95%CI 7.0%-17.6%)。
  • 诱导化疗(两组均含同期化疗)HR 0.73(95%CI 0.63-0.86),5年绝对生存获益6.0%(95%CI 2.5%-9.5%)。
  • 同期化疗HR 0.81(95%CI 0.70-0.92),5年绝对生存获益5.2%(95%CI 0.8%-9.6%)。

关键数值与推荐

  • 化疗联合放疗较单纯放疗降低死亡风险,HR 0.79(95%CI 0.73-0.85)。
  • 同期+辅助化疗HR 0.68(95%CI 0.59-0.79),诱导化疗HR 0.73(95%CI 0.63-0.86),同期化疗HR 0.81(95%CI 0.70-0.92)。
  • 化疗获益还体现在无进展生存、肿瘤死亡率、局部区域控制和远处控制的改善。
  • 患者年龄与化疗效应之间存在显著交互作用。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 18项新检索到的试验中仅7项可获得个体患者数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemotherapy, when added to radiotherapy, improves survival in locally advanced nasopharyngeal carcinoma (NPC). This article presents the second update of the Meta-Analysis of Chemotherapy in NPC. METHODS: Published or unpublished randomized trials assessing radiotherapy (±a second chemotherapy timing) with/without chemotherapy in non-metastatic NPC patients were identified. Updated data were sought for studies included in the previous rounds of the meta-analysis. The primary endpoint was overall survival. All trials were analyzed following the intent-to-treat principle using a fixed-effects model. Treatments were classified in five subsets according to chemotherapy timing. The statistical analysis plan was pre-specified. RESULTS: Eighteen new trials were identified. Individual patient data were available for seven. In total, the meta-analysis now included 26 trials and 7,080 patients. The addition of chemotherapy reduced the risk of death, with a hazard ratio (HR) of 0.79 (95% confidence interval (CI) [0.73; 0.85]), and an absolute survival increase at 5 and 10 years of 6.1% [+3.9; +8.3] and + 8.4% [+5.7; +11.1], respectively. The largest effect was observed for concomitant + adjuvant, induction (with concomitant in both arms) and concomitant chemotherapy, with respective HR [95%CI] of 0.68 [0.59; 0.79] (absolute survival increase at 5 years: 12.3% (7.0%;17.6%)), 0.73 [0.63; 0.86] (6.0% (2.5%;9.5%)) and 0.81 [0.70; 0.92] (5.2% (0.8%;9.6%)). The benefit of chemotherapy was also demonstrated by improvement in progression-free survival, cancer mortality, locoregional control and distant control. There was a significant interaction between patient age and chemotherapy effect. CONCLUSION: This updated meta-analysis confirms the benefit of concomitant chemotherapy and concomitant + adjuvant chemotherapy, and suggests that addition of induction or adjuvant chemotherapy to concomitant chemotherapy improves tumor control and survival. The benefit of chemotherapy decreases with increasing patient age.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Blanchard P, Lee AWM, Carmel A, et al. Meta-analysis of chemotherapy in nasopharynx carcinoma (MAC-NPC): An update on 26 trials and 7080 patients. Clin Transl Radiat Oncol. 2021. PMID: 34935776. doi:10.1016/j.ctro.2021.11.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。